Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Descriptor ID |
D002295
|
| MeSH Number(s) |
C04.557.470.200.430
|
| Concept/Terms |
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1998 | 3 | 0 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 4 | 0 | 4 |
| 2002 | 2 | 0 | 2 |
| 2003 | 3 | 0 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 1 | 4 |
| 2008 | 6 | 0 | 6 |
| 2009 | 2 | 0 | 2 |
| 2010 | 4 | 0 | 4 |
| 2011 | 2 | 0 | 2 |
| 2012 | 4 | 0 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 8 | 0 | 8 |
| 2018 | 5 | 1 | 6 |
| 2019 | 8 | 0 | 8 |
| 2020 | 8 | 2 | 10 |
| 2021 | 6 | 1 | 7 |
| 2022 | 10 | 0 | 10 |
| 2023 | 5 | 0 | 5 |
| 2024 | 4 | 4 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update. J Am Coll Radiol. 2024 Nov; 21(11S):S464-S489.
-
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011. Cancer. 2025 Jan 01; 131(1):e35601.
-
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov; 10(11):1565-1570.
-
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2025 Jan 02; 392(1):45-55.
-
Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature. Histopathology. 2024 Nov; 85(5):748-759.
-
Giant cell carcinoma of the urinary bladder : Clinicopathologic analysis and oncological outcomes. Virchows Arch. 2024 Sep; 485(3):535-546.
-
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy. Eur Urol. 2024 Jun; 85(6):574-585.
-
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. J Clin Oncol. 2024 Apr 20; 42(12):1403-1414.
-
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. 2024 Aug; 7(4):933-943.
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2024 Jan; 25(1):29-45.